Pharmacology, Toxicology and Pharmaceutical Science
Eribulin
100%
Agonist
72%
Triple Negative Breast Cancer
36%
Clinical Trial
27%
Beta Interferon
18%
Synergism
18%
Cancer Model
18%
Neoplasm
9%
RNA
9%
Paclitaxel
9%
Breast Tumor
9%
Cytokine
9%
Transcription Factor
9%
Tumor Model
9%
Immunotherapy
9%
Antimitotic Agent
9%
Taxane
9%
Drug
9%
Mitochondrial DNA
9%
Adjuvant
9%
Interferon Regulatory Factor 3
9%
Immunology and Microbiology
Microtubule
54%
Agonist
36%
Breast
36%
Aptitude
27%
Beta Interferon
18%
Immunity
18%
Degradation
9%
Transcription Factor
9%
Phosphorylation
9%
Signal Transduction
9%
Immunotherapy
9%
Cell Migration
9%
IRF3
9%
Adjuvant
9%
Immunocompetent Cell
9%
T-Helper Cell
9%
Neuroscience
Eribulin
100%
Agonist
36%
Beta Interferon
18%
RNA
9%
In Vivo
9%
Cell Signaling
9%
Phosphorylation
9%
Transcription Factors
9%
Paclitaxel
9%
Taxane
9%
Mitochondrial DNA
9%
Cell Migration
9%
Immunotherapy
9%
IRF3
9%
Chemistry
Eribulin
100%
Antitumor
18%
Paclitaxel
9%
Phosphorylation
9%
Antimitotic
9%
Taxane
9%
Adjuvant
9%
Chemical Activation
9%
RNA
9%
Point Group T
9%
Degradation
9%
Mitochondrial DNA
9%
Biochemistry, Genetics and Molecular Biology
Agonist
36%
Aptitude
27%
Cytokine
18%
Phosphorylation
9%
Signal Transduction
9%
Transcription Factor
9%
Cell Migration
9%
Degradation
9%
IRF3
9%
Mitochondrial DNA
9%
Immunocompetent Cell
9%